Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., . . . Kagamu, H. (2019). Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Wiley.
Παραπομπή Chicago StyleYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
Παραπομπή MLAYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.